DOCSLIB.ORG

Growing Together More Closely We Are Keen to Make Their Processes More Efficient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Growing Together More Closely We Are Keen to Make Their Processes More Efficient Growing together ANNUAL REPORT ANNUAL REPORT 2013 REPORT ANNUAL | LUBRICANTS. TECHNOLOGY. PEOPLE. FUCHS PETROLUB SE FUCHS PETROLUB is a global Group based in Germany, which produces and distributes lubricants and related specialties around the world. The Group, which was founded in 1931, with its headquarters in Mannheim, ranks num- ber one among the world’s independent lubricant providers. The Group currently employs a workforce of 3,888 in 50 operating companies in Europe and overseas. The most important regions for FUCHS in terms of sales revenues are Western Europe, Asia and North America. For 83 years, we have been concentrating all of our efforts and ideas on the development of innovative lubricants. We provide special lubricant solutions in market niches and offer our customers support in the world‘s key growth countries. Our local presence, coupled with the expertise and special understanding of values displayed by our employees, enables us to cater to individual customer requirements with tailor-made products. In this endeavor, we strive to utilize the strength of our global network and continue to grow as group. This is how we generate sustainable added value for our customers and all other stakeholders. FUCHS at a glance FUCHS PETROLUB GROUP Change Amounts in € million 2013 2012 in % Sales revenues 1 1,831.6 1,819.1 0.7 Europe 1,104.2 1,080.7 2.2 Asia-Pacifi c, Africa 497.9 486.8 2.3 North and South America 307.3 320.3 – 4.1 Consolidation – 77.8 – 68.7 13.2 Earnings before interest, tax and income from companies consolidated at equity 298.8 278.8 7.2 in % of sales revenues 16.3 15.3 Earnings before interest and tax (EBIT) 312.3 293.0 6.6 Earnings after tax 2 218.6 207.0 5.6 in % of sales revenues 11.9 11.4 Investments in long-term assets 72.8 71.4 2.0 in % of scheduled depreciation 3 253 227 Gross cash fl ow 224.6 219.0 2.6 Shareholders’ equity 853.5 781.7 9.2 in % of balance sheet total 73.5 70.5 Balance sheet total 1,162.0 1,108.7 4.8 Employees as at December 31 3,888 3,773 3.0 Earnings per share (in €) Ordinary share 3.06 2.90 5.5 Preference share 3.08 2.92 5.5 Proposed dividend / dividend (in €) per ordinary share 1.38 1.28 7.8 per preference share 1.40 1.30 7.7 1 By company location. 2 Previous year´s fi gures adjusted, see “Application of new accounting standards” in the notes to the consolidated fi nancial statements. 3 Capital expenditure excluding fi nancial assets. GROUP STRUCTURE The Group is headed by the central-management controlling company, FUCHS PETROLUB SE, which predominantly owns subsidiaries directly at 100%. On December 31, 2013, the Group comprised 50 operating companies. The consoli- dated fi nancial statements also include non-operating holding companies, management companies and real-estate companies, thus increasing the number of consolidated companies to 52. Of the 50 operating companies, fi ve conducted their business activities in Germany and 45 abroad. 81 The organizational and reporting structure is divided into the following regions: Results of operations Europe, Asia-Pacifi c, Africa and North and South America. of the regions 5 Group companies and FUCHS at a glance production locations FUCHS A GLANCE AT PRODUCTION LOCATIONS GROUP COMPANIES AND PRODUCTION LOCATIONS As at December 31, 2013 Group companies 1 Production locations Germany 5 6 Other European countries 22 7 Asia-Pacifi c 17 8 Africa 1 1 North America 3 7 South America 2 2 Total 50 31 1 Operating companies. 2 Content 4 VALUES 18 portraits of FUCHS employees 3 12 Top performance – special medical engineering solutions 4 Growth course – interview with the Chairman of the Executive Board Stefan Fuchs 8 FUCHS in figures 10 On the Pulse – new production site in China 12 Values – portraits of FUCHS employees 18 5 TOP PERFORMANCE Medical engineering is an exciting growth sector. FUCHS develops h igh- performance cutting fluids for the manufacture of implants and has been able to impress a group of discerning customers with its innovative power. Text by Silke Wernet 6 The field of medical engineering is booming. This can largely Besides the specific performance,FUCHS therefore also be attributed to the ever-increasing life expectancy of carries out comprehensive, in-depth tests of the long-term human beings and a heightened sense of awareness for availability of the raw mate rials used, as well as their com- health issues, as well as the rapid population growth patibility for human beings. being encountered in the emerging markets, which stimu- lates demand. However, the recent growth in this sector CYTOTOXICOLOGICAL TESTS would not even be possible without the specialized produc- Manufacturers of knee and hip implants or dental implant tion technology now available. pins always ensure that their products are absolutely media- free and sterile before they are implanted in the human The global market for medical equipment, surgical instru- body. However, a microscopic amount of residue, for example ments, and in particular implants, which can significantly from a cutting fluid, can lead to potential compli cations, improve the quality of life for patients, generated revenue of even after extremely intensive cleaning. “This is a highly sen- around € 221 billion in 2012 and is growing at a steady sitive sector, for which we pre-screen our raw materials and rate of around 7 % per year. The US represents the largest subject them to rigorous testing procedures,” stresses Frank market and, with revenue of around € 22 billion, Germany Thomas. The influence of all cutting fluids is therefore tested was the number three player in the global business. Medical thoroughly, including their influence on cell growth. Products engineering is a sector of the future, for which FUCHS that have passed the test include PLANTOCUT 10 SR, a EUROPE SCHMIERSTOFFE has been developing innovative, cutt ing fluid made from synthetic ester oils based on renew- high-performance products for more than ten years. able raw materials that is kind to skin and quickly biodegrad- able. “These cytotoxicological tests offer manufact urers and The requirements of cutting fluids in the medical engi- users the highest degree of security,” stresses the chemical neering sector are vast. Besides stainless steels, the sector engineer. “And they are a USP that helps us stand out from is now increasingly using titanium and cobalt alloys in the rest of the market.” This also applies to service, as the manu facture of implants. These materials excel through FUCHS offers a complete all-around package – from initial their strength, but precisely this strength also makes consulting, all the way through to r egular process checks the metal cutting processes employed during production, on the customer’s premises. such as drilling or milling, more difficult. This requires engineering excellence which is also needed from the cut- GLOBAL EXCHANGE ting fluid. To this end, the specialists atFUCHS develop Our specialist knowledge of these cutting fluids is not reserved solutions tailored specifically to the respective process or exclusively for our own laboratories. Indeed, a comprehen- application. “We take the highly specific requirements of sive international employee network, which FUCHS is keen our customers into our laboratory,” explains Frank Thomas, to further expand over the course of the next few years, Head of the “Non water miscible cutting and quenching ensures that the results of new research activities and infor- fluids” unit. “Quality”, adds Dr. Christine Fuchs, Head of mation on innovative technological processes flow into Global R & D, “is immensely important in this regard.” the Group’s various locations around the globe. “We have an » We can supply the medical engineering market at a very high level and on a global scale. « Dr. Christine Fuchs, Head of Global R & D, FUCHS EUROPE SCHMIERSTOFFE 7 left // Spinal implant in the human body. top right // For Head of Development Frank Thomas, medical engineering is a market of the future. bottom right // The basis of success: the right concen­ tration of the right raw material. excellent global network, which provides us with synergy pass on their own special knowledge to other fields too – for effects for research and development,” underlines Dr. Christine example the automotive industry, which is increasingly Fuchs. “And we are able to guarantee our high quality requiring high strength and heat-resistant materials due to standards worldwide.” the trend toward lightweight construction and downsizing. The chemical engineer is keen to stress that these synergies THE FUTURE LIES IN MAGNESIUM have also been filtering through to other sectors for some Whenever taking a look into the future of medical engineer- time. For example, FUCHS has already been able to gather ing, researchers and developers quickly turn to the topic valuable experience in the field of titanium cutting for the of magnesium alloys. Screws and plates made of magnesium aerospace industry, which proved extremely useful to the can be fully broken down by the human body. In future, a experts when developing cutting fluids for the field ofmedi - broken bone may then no longer require any further surgical cal engineering. The Head of R & D and her colleague agree: intervention. This is a potentially far-reaching future tech - “FUCHS is present in many fields, and we all draw benefits no logy, for which FUCHS already has suitable products in its from the comprehensive overall experience within the portfolio and which can make the whole experience far company.” The two staff members were therefore able to less stressful for patients. 8 GROWTH COURSE Stefan Fuchs takes a glimpse into a successful future.
Load more

Recommended publications
  • Welcoming 62 New EMBO Members Marek Basler & Melina Schuh
    SUMMER 2018 ISSUE 39 Scientists from 24 countries elected Welcoming 62 new EMBO Members PAGES 4 – 5 Research assessment EMBO Gold Medal 2018 Kicking the impact Marek Basler & Melina Schuh honoured factor habit PAGE 3 PAGE 11 Creative collaborations Learning to lead Fellowship application EMBO Young Investigators EMBO Lab Leadership courses Tips and tricks on structuring share their stories in the spotlight a project proposal PAGES 6 – 7 PAGES 8 – 9 PAGE 12 www.embo.org TABLE OF CONTENTS © Marietta Schupp, EMBL Photolab Marietta Schupp, © Meet the 62 new EMBO Members Editorial PagesEMBO NEWS4-5 he first EMBO Gold Medal was present- ed to John Tooze in 1986. Since then, it Thas been awarded annually to celebrate EMBO news EMBO community the scientific achievements of young scien- tists. The work of this year’s recipients, Marek Two EMBO Gold Medals awarded Page 3 Updates from across Europe Basler and Melina Schuh (see p 3), continues Pages 14 – 16 in the same vein, exemplifying the exciting research that takes place across Europe. Each year, we ask our Members and Young Awards and publications Investigators to nominate candidates for the Gold Medal. Selecting one, or sometimes two, Achievements and papers by members of recipients from the many deserving nominees the EMBO community Page 17 is not an easy task. To make the selection process as fair as possible, we have changed the way EMBO Council assesses and discusses Crossing EMBO events each candidate. continents As one of the original signatories of the San Upcoming courses, workshops and Francisco Declaration on Research Assessment conferences Page 18 (DORA), we believe that the way research- ers and their work are assessed must change.
    [Show full text]
  • Art + Design : News + Notes
    ART + DESIGN : NEWS + NOTES COLLEGE OF ARCHITECTURE AND DESIGN – NEW JERSEY INSTITUTE OF TECHNOLOGY – NEWARK, NEW JERSEY – OCTOBER 2015 School of Art + Design Receives NASAD Accreditation Digital Design Student Animation Selected for Screening at MetroCAF 2015 in New York City The School of Art + Design successfully “Voice,” a completed its efforts in music and obtaining accreditation geometry- from the National inspired Association of Schools animation of Art and Design created in (NASAD). All three undergraduate four-year programs a second (Bachelor of Arts in Digital Design, Bachelor of Science year class in Industrial Design, and Bachelor of Arts in Interior by Digital Design student Nathalie Carrasco, was Design) in the School of Art + Design were accredited. selected and screened at MetroCAF 2015 on Friday, The Visiting Team described the efforts and impact of September 25. “MetroCAF is the annual New York City the School as “vibrant and commendable.” Metropolitan Area College Computer Animation Festival organized by the New York City ACM SIGGRAPH The accreditation was achieved through a collaborative Professional Chapter.” Eligibility extends to all students effort that required written reports, digital exhibit and attending a school within a 160-mile radius of Times physical exhibits of student work, and evidence of Square in New York City. Augustus Wendell, principal participation in regional and national arts communities and creative director of Kim.Wendell Design, LLC in and activities. Brooklyn, and Coordinator of the Digital Design program, was selected to serve on the MetroCAF jury. This achievement completes the suite of accreditations for the College of Architecture and Design in the last two years: CIDA (Interior Design); NAAB (Architecture); Recent Interior Design Graduate and Faculty NASAD (Art + Design).
    [Show full text]
  • YEARBOOK  Medicinal Chemistry in Europe
    EFMC YEARBOOK Medicinal Chemistry in Europe EFMC-ISMC 2020 EFMC-YMCS 2020 EFMC-ASMC’19 Basel, Switzerland Basel, Switzerland EFMC-YMCS 2019 September 6-10, 2020 September 10-11, 2020 Special reports EFMC International Symposium on Medicinal Chemistry Basel, CH September 6-10, 2020 SESSIONS AND SESSION COORDINATORS EFMC AWARD LECTURES CHEMICAL BIOLOGY THERAPEUTIC AREAS – The Nauta Pharmacochemistry Award – The UCB-Ehrlich Award for Excellence in Medicinal CARBOHYDRATE RECOGNITION AND DRUG DESIGN ADDRESSING NEGLECTED AND EMERGING VIRAL Chemistry Alexander Titz (Helmholtz Institute for Pharmaceutical DISEASES WITH SMALL MOLECULES AFMC Session – The Prous Institute-Overton and Meyer Award for New Sciences, DE) Esin Aki-Yalçin (Ankara University, TR) Technologies in Drug Discovery CHEMICAL APPROACHES TO STEM CELL BREATHING LIFE INTO INHALED DRUG DISCOVERY: DIFFERENTIATION ICBS Session CHALLENGES AND BREAKTHROUGHS TO THE CLINIC EFMC PARTNER PRIZES Colin Pouton (Monash University, AU) ACSMEDI Session Nicole Goodwin(GSK, US) – The IUPAC-Richter Prize in Medicinal Chemistry CHEMICAL PROBES FOR TARGET DISCOVERY AND – The Klaus Grohe Prize VALIDATION CHEMICAL TOOLS AND DRUG DISCOVERY FOR Gyorgy Keseru (Hungarian Academy of Sciences, HU) NEUROINFLAMMATION EUCHEMS Session EFMC PRIZE LECTURES Sonsoles Martin-Santamaria (Biological Research Center, ES) MOLECULAR IMAGING TOOLS FOR CHEMICAL BIOLOGY Valle Palomo (CIB, ES) NEW STRATEGIES AND AGENTS FOR TARGETING – EFMC Prize for a Young Medicinal Chemist in Industry GRAMNEGATIVE PATHOGENS – EFMC Prize
    [Show full text]
  • Crystallography News British Crystallographic Association
    Crystallography News British Crystallographic Association Issue No. 119 December 2011 ISSN 1467-2790 22nd Congress of the IUCr in Madrid p6 BCA Meeting 2012 p12 National Facilities News p16 SAXS Course Leeds 2012 p24 ThreeThree Whishes Whishes Granted...Granted... TheThe new new D8 D8 VENTURE VENTURE withwith PHOTON PHOTON 100 100 zzHighzzHigh Performance Performance zzLowzz LowMaintenance Maintenance zzBrightestzzBrightest Microfocus Microfocus The D8The VENTURE D8 VENTURE is the is perfect the perfect answer answer to all to your all yourquestions questions in single in single crystal crystal X-ray X-ray structurestructure determination. determination. The D8The VENTURE D8 VENTURE features features excellent excellent sample sample access access and and visibility.visibility. The patentedThe patented doors doors either either can becan opened be opened in a sliding-door-modein a sliding-door-mode or as or swinging as swinging doors.doors. In addition In addition to single to single source source configurations configurations the theD8 VENTURED8 VENTURE accommodates accommodates dual dual wavelengthwavelength configurations. configurations. Based Based on the on principlesthe principles of DAVINCI.DESIGN of DAVINCI.DESIGN it is itengineered is engineered with withhigh highmodularity modularity from from best-in-class best-in-class components. components. www.bruker.comwww.bruker.com SC-XRDSC-XRD InnovationInnovation with with Integrity Integrity D8 VENTURED8 VENTURE 8.375 x 11.1258.375 xinch 11.125 2011.indd inch 2011.indd 1 1 07.06.201107.06.2011 14:23:19 14:23:19 EMPYREAN 100M 10M 1M The world of X-ray diffraction 0D Intensity [counts] 100K 10K 1K is no longer fl at 100 10 -6000 -4000 -2000 0 2000 4000 6000 Omega/2Theta [s] Intensity [counts] FWHM = 0.026 °2 1D 4000 θ Intensity [counts] 3000 Position 2Theta [deg.] (Copper Cu)) 2000 1000 0 20 30 40 50 60 70 80 90 100 110 120 130 140 Position 2Theta [deg.] (Copper (Cu)) 2D 3D The new Empyrean from PANalytical The only XRD platform is truly innovative, with cutting-edge technology in every aspect.
    [Show full text]
  • Sculpture Trail Leaflet
    1 nechemia azaz 1923–2008 natural growth, ripeness and fecundity. Of this welder. After the war he attended the Central created millions of years ago. He uses a piece Randall-Page wrote: ‘I have tried to make School of Arts and Crafts and became a full- pneumatic drill to make holes which join in Op Mobile No 10 1974 a sculptural equivalent of an emotional state time sculptor. the centre of the rocks and then carves shapes – the dark knotted centre, the consciousness around some of the holes, creating curious Painted aluminium tubing This architectural work is a focal point of of being alone’. protrusions. Sound is an element in these Purchased by the University Rootes Square, where its bright colour and works so if you gently hit your hand against curved forms stand in contrast to the angular Azaz was born in Berlin yet spent his childhood these, percussive sounds are made. Two of 5 avtarjeet dhanjal b 1940 sixties architecture of the student residences. in Palestine. After training as a stonemason the pieces incorporate an electronic device Austerely abstract, as underlined by its title in Bologna he studied sculpture in the which transmits natural sounds the artist has Grown in the Field 1976 3B Series I, it utilises industrial materials and Netherlands and Paris. recorded. Aluminium methods of production. The careful positioning This brightly coloured mobile reflects the Commissioned and presented to the University by of different shapes draws attention to the original colour scheme of the Arts Centre, Alcan Aluminium (UK) Ltd, 1977 internal negative spaces they define.
    [Show full text]
  • YEARBOOK 2021 | 1 Editorial
    EFMC Yearbook 2021 Medicinal Chemistry and Chemical Biology in Europe EFMC-ISMC International Symposium on Medicinal Chemistry Virtual Event Aug. 29-Sept. 2, 2021 SESSIONS AND SESSION NEXT GENERATION DRUGS FOR HEART CONFIRMED PLENARY LECTURES COORDINATORS FAILURE Alleyn Plowright, Wren Therapeutics, UK Phil Baran, The Scripps Research Institute, US CHEMICAL BIOLOGY Karin Briner, Novartis, US RECENT ADVANCES IN ANTICANCER DRUG Jean-Paul Clozel, Idorsia, CH CARBOHYDRATE RECOGNITION AND DRUG DISCOVERY Stefan Knapp, Goethe University Frankfurt, DE DESIGN Roberto di Santo, Sapienza University of Rome, IT Alexander Titz, Helmholtz Institute for Pharmaceutical Sciences, DE TARGETING FIBROTIC DISEASES WITH SMALL MOLECULES EFMC AWARD LECTURES CHEMICAL APPROACHES TO STEM CELL Boehringer Ingelheim, DE DIFFERENTIATION (ICBS Session) THE NAUTA PHARMACOCHEMISTRY AWARD Colin Pouton, Monash University, AU TISSUE AND CELL SPECIFIC DRUG DELIVERY FOR MEDICINAL CHEMISTRY AND CHEMICAL (EUFEPS Session) BIOLOGY CHEMICAL PROBES FOR TARGET DISCOVERY Sébastien Papot, University of Poitiers, FR Ad P. Ijzerman, Leiden University, NL AND VALIDATION Gyorgy Keseru, Hungarian Academy of Sciences, HU TECHNOLOGIES IN MEDICINAL CHEMISTRY MOLECULAR IMAGING TOOLS FOR CHEMICAL Malin Lemurell, AstraZeneca, SE BIOLOGY APPLICATION OF ARTIFICIAL INTELLIGENCE Valle Palomo, CIB, ES IN DRUG DISCOVERY PROJECTS Christopher Swain, Cambridge MedChem AWARD FOR NEW TECHNOLOGIES IN DRUG PHOTOCHEMISTRY IN DRUG DISCOVERY: Consulting, UK DISCOVERY PHOTOPHARMACOLOGY, PHOTOTOXICITY Gisbert Schneider, ETH Zürich, CH AND SYNTHESIS (ACSMEDI Session) BIOCATALYSIS & LATE STAGE Timothy Henderson, MSD, US & Amjad Ali, MSD, US FUNCTIONALISATION Radka Snajdrova, Novartis, CH EFMC PARTNER PRIZES SMALL MOLECULES TARGETING RNA FUNCTION AND PROCESSING Maria Duca, University of Côte d'Azur, FR Jean-Paul Renaud, Urania Therapeutics, FR John E. Macor, Sanofi, US TARGET DECONVOLUTION STRATEGIES IN THE KLAUS GROHE AWARD DRUG DISCOVERY EXPANDING CHEMICAL SPACE THROUGH Stephan A.
    [Show full text]
  • 3.1 Consolidated Financial Statements of FUCHS PETROLUB SE
    ANNUAL REPORT 2018 Pacesetter FUCHS PETROLUB SE | ANNUAL REPORT 2018 “ Technological advances, new possibilities within the Brief profile Brief – digital world, autonomous driving, e-mobility – these are all challenges that we want Locations – to use as opportunities. Our aim is to create a more agile company based on our values – Group structure Group with communication free – of hierarchies and with an open feedback culture.” Stefan Fuchs, Chairman of the Executive Board FUCHS at a glance a at FUCHS 2018 in 18 seconds € 2,567 million 2,473 2017 2018 EBIT € 383 million Sales + 4 % 14.9 % of sales R & D expenses 5,446 employees € 52 million (+ 256 ) FUCHS at a glance FUCHS Group Amounts in € million Change 2018 2017 in % Sales revenues 1 2,567 2,473 3.8 Europe 1,546 1,515 2.0 Asia-Pacific, Africa 783 733 6.8 North and South America 409 393 4.1 Consolidation – 171 – 168 1.8 Earnings before interest and tax and before income from companies consolidated at equity 357 356 0.3 in % of sales revenues 13.9 14.4 Earnings before interest and tax (EBIT) 383 373 2.7 Earnings after tax 288 269 7.1 in % of sales revenues 11.2 10.9 Investments in long-term assets 121 105 15.2 in % of scheduled depreciation 2 209 198 Free cash flow before acquisitions 3 147 142 3.5 Shareholders' equity 1,456 1,307 11.4 in % of balance sheet total 77.0 74.6 Balance sheet total 1,891 1,751 8.0 Employees as at December 31 4 5,446 5,190 4.9 Earnings per share (in €) Ordinary share 2.06 1.93 6.7 Preference share 2.07 1.94 6.7 Proposed dividend / dividend (in €) per ordinary share 0.94 0.90 4.4 per preference share 0.95 0.91 4.4 1 By company location.
    [Show full text]
  • Bioorganic & Medicinal Chemistry, Volume 11, Dec, 2003
    MMCC Results Volume 15 No. 2 1 June 2006 Vol. 15, No. 2 1 June 2006 Coverage period: 1 April 2006 through 31 May 2006 Editorial and News About 105 papers from 20 journals are cited. As mentioned last month, the majority of the journal 1. APPLICATIONS ( 78 ) . page 2 reviews are now covered in the main section of the 1.1 Small Molecules – 40 reviews. General & Model systems-1 QSAR — 19 Water and Solvation – 2 Host-guest systems-4 I would call your attention on few highlighted Med Chem & Drug Design – 10 Carbon Nanoparticles – 3 articles, particularly in the Methodology section related to Liquid crystals-1 potentials and parameters. 1.2 Biopolymers – 34 R.Nageswar, Editor Bioinformatics – 3 Protein Dynamics – 5 Protein Folding - 1 Ligand Binding – 7 Protein Structure Prediction – 2 Protein-Protein Inter. – 2 Comp and Homol Modeling – 6 Membrane Proteins — 1 Protein Folding – 1 Free energy- 4 Protein Engg. & Design -2 1.3 Polymers – 1.4 Surfaces, Catalysts, and Materials Subjects — 5 2. METHODOLOGY (32) . page 19 QSAR - 4 Homology modeling – 1 Conformational Search & Anal -2 Mol.Graphics-2 Potentials and Parameters - 4 Ligand Docking — 4 Molecular Dynamics – 3 Surface volme - 1 QM/MM - 9 Protein structure prediction-2 3. JOURNAL REVIEWS (38) . page 26 J. Comp. Chem. 27 (8), 1 June 2006 J. Comp. Chem. 27 (9), 15 July 2006 J. Comp. Chem. 27 (10), 30 July 2006 Current Opinion in Structural Biology 16 (2) April 2006 4. ADDRESSES OF PRINCIPLE AUTHORS page 31 5. COPYRIGHT, DISCLAIMER AND PUBLISHER INFORMATION Page 1 1 June 2006 MMCC Results Volume 15 No.
    [Show full text]
  • Modern British Art in Finland, 1906–1964
    Issue No. 4/2016 ‘New relations, unsuspected harmonies’: Modern British Art in Finland, 1906–1964 Inga Fraser // Assistant Curator of Modern British Art, Tate, London __________ The above quotation1 is taken from a description penned by Roger Fry of a painting by Paul Cézanne, Les Maisons Jaunes, (1879–82), now known as The Viaduct at L’Estaque, which was shown at the exhibition, ‘Manet and the Post-Impressionists’, at the Grafton Galleries in London from 8 November, 1910 to 11 January, 1911. This work was acquired for the collection of the Finnish Art Society at the Art Museum of the Ateneum in Helsinki,2 following discussion involving the London-based Finnish art historian Tancred Borenius and the Finnish professor of aesthetics and literature Yrjö Hirn. Copies of the letters between Borenius and Hirn held in the archive collections of the Finnish National Gallery show the extent to which Fry influenced this particular acquisition. Borenius refers to Fry’s direct involvement in the selection of acquisitions, recommends Fry to Hirn as one of Europe’s foremost connoisseurs and, finally, mentions the fact that Fry promised to publish a written appraisal of the acquisition in The Burlington Magazine, thus validating the quality and value of the painting in the eyes of the public. With increasing infrastructure and affluence in the first half of the 20th century, travel and international communications became more viable for artists, critics, scholars and collectors alike in Europe. Consequently, the period 1905–65 was witness to the rapid expansion of the art market. National museums in a number of European capitals outside the established art market centres of London, Paris, Vienna, Moscow and St.
    [Show full text]
  • Facts & Figures Excellence in Life Sciences
    excellence in life sciences Reykjavik Helsinki Oslo Tallinn Stockholm Copenhagen Vilnius Dublin Amsterdam Berlin Warsaw London Brussels Prague Bratislava Paris Luxembourg Budapest Bern Vienna Ljubljana Zagreb Podgorica Madrid Rome Ankara Lisbon Athens Valletta Jerusalem New Delhi Singapore EMBO facts & figures EMBO table of contents EMBO Fellowships 24 – 71 Prefaces 4 – 5 EMBO Long-Term Fellowships 24 – 41 EMBO actions in 2018 6 – 7 Statistics 24 – 25 EMBC actions in 2018 8 – 9 Awards 2018 26 – 41 Geographical distribution 2018 42 – 43 EMBO Advanced Fellowships 44 facts & figures 2018 EMBO Short-Term Fellowships 45 – 75 Statistics 45 EMBC Member States 12 – 13 Awards 2018 46 – 72 Delegates and Advisers 12 Geographical distribution 2018 74 – 75 Financial contributions 13 EMBO Young Investigators 76 – 81 EMBO Council & Committees 14 – 15 Young Investigators 2018 76 – 77 EMBO Council 2018 14 Applications and awards 2014 – 2018 78 EMBO Committees 2018 15 Lectures 2018 79– 81 EMBO Membership 16 – 19 EMBO Installation Grants 82 EMBO Members 2018 16 – 18 Installation Grantees 2018 82 EMBO Associate Members 2018 19 EMBO Courses & Workshops 83 – 87 EMBO Scientific Publications 20 – 23 Practical Courses 2018 83– 84 Advisory Editorial Boards & Editors of Workshops 2018 84 – 87 The EMBO Journal 20 EMBO | FEBS Lecture Courses 2018 87 EMBO Reports 21 India | EMBO Symposia 87 Molecular Systems Biology 22 EMBO Keynote Lectures 89 – 91 EMBO Molecular Medicine 23 Keynote Lectures 2018 89 – 91 EMBO Gold Medal 92 Gold Medalists 1986 – 2018 92 EMBO Women in Science 93 – 95 Participation of women in EMBO activities: Statistics 93 – 95 EMBO staff in Heidelberg 96 – 97 EMBO facts & figures 2018 | www.embo.org 1 Short-Term Fellowships to researchers at all career stages and from all disciplines across the life sciences.
    [Show full text]
  • FALL2012RS.Pdf
    American Crystallographic Association Cover: Depicts the swinging domain motion required for the methyl hand-off between two B vitamins. Image supplied ACA RefleXions by Yan Kun and Cathy Drennan; see the Fall, 2012 article on page 3. ACA HOME PAGE: www.AmerCrystalAssn.org Table of Contents 2 ACA RefleXions Co-Editors & Staff 3 President’s Column What's on the Cover 4 Council Highlights News from Canada 6 Jane Griffin joinsRefleXions Staff News, Announcements 7-9 Awards, Science News, Scholarships, Travel Funds 11 Ray Young (1921-2012) 12-13 2012 ACA Poster Prizes in Boston 14-64 2012 ACA Meeting in Boston 51 Index of Advertisers 68 International School of Crystallography at Erice 66-67 Book Reviews 72 Contributors to this Issue Workshop on Photocrystallographic Methods 73 ACA Summer Course in Chemical Crystallography 74-75 2013 ACA Meeting in Hawaii 77 Corporate Members 78 Puzzle Corner 80 Calendar of Meetings Contributions to ACA RefleXions may be sent to either of the Editors: Please address matters pertaining to advertisements, membership inquiries, or use of the ACA mailing list to: Connie (Chidester) Rajnak Judith L. Flippen-Anderson 4210 Old Field Trail 3521 Launcelot Way Marcia J. Colquhoun, Director of Administrative Services Kalamazoo, MI 49008 Annandale, VA 22003 American Crystallographic Association P.O. Box 96, Ellicott Station 269-342-1600 703-346-2441 Buffalo, NY 14205 [email protected] [email protected] tel: 716-898-8692; fax: 716-898-8695 [email protected] Deadlines for contributions are: February 1 (Spring), May 1 (Summer), August 1 (Fall) and November 1 (Winter) ACA RefleXions (ISSN 1058-9945) Number 1 2012.
    [Show full text]
  • Zelluläre (Re)Aktionen Cells in (Re)Action Bmls = Buchmann Institute for Molecular Life Sciences Zelluläre (Re)Aktionen Cells in (Re)Action
    ZELLULÄRE (RE)AKTIONEN CELLS IN (RE)ACTION BMLS = BUCHMANN INSTITUTE FOR MOLECULAR LIFE SCIENCES ZELLULÄRE (RE)AKTIONEN CELLS IN (RE)ACTION Josef- Buchmann- Stiftung AUF EIN VORWORT Wir sind stolz auf Erreichtes, und blicken selbstbewusst in die Lebens- und Naturwissenschaften und der Leitung der Goethe- Zukunft. Das Buchmann Institut hat die ersten fünf Jahre mit Universität, in diesen Leuchtturm der Frankfurter Wissenschaft Bravour gemeistert und wir haben uns zu einem Spitzeninstitut im Rahmen des Exzellenzclusters „Makromolekulare Komplexe“ Deutschlands im Bereich der Molekularen Lebenswissenschaften zu investieren. Diesem Vertrauen von Bund, Land, Stifter und entwickelt. Das ist uns vor allem durch herausragende wissen- Kolleginnen und Kollegen fühlen wir uns verpflichtet. schaftliche Beiträge gelungen. Wir forschen im Bewusstsein, dass nur aus der Symbiose zwischen Grundlagenforschung Wir diskutieren unsere Ergebnisse nicht nur mit Wissenschaft- und interdisziplinärem Dialog die wahren Innovationen entste- lerinnen und Wissenschaftlern aller Kontinente, wir transpor- hen, und diese Idee setzen wir am BMLS täglich um. Machen Sie tieren unsere Begeisterung und unsere Wissenschaft auch in sich selbst ein Bild, begleiten Sie uns auf der Reise durch die die Gesellschaft, sei es auf öffentlichen Foren, Vorträgen und Zelle und unser Institut! Diskussio nen, in Gesprächen oder organisierten Praktika für Schülerinnen und Schüler, an Tagen der offenen Tür oder in Ermöglicht wurde dieses Institut durch das Aufeinandertreffen Form dieses Zwischenberichtes – selbiger ist unter Mitwirkung von drei Triebkräften der Innovation. Die außerordentliche und aller Kolleginnen und Kollegen entstanden. Mein besonderer überaus erfolgreiche Exzellenzinitiative des Bundes und der Dank gilt Anja Sälzer, der Managerin des Institutes, die uner- Länder war, allen Zweiflern zum Trotz, eine Vitaminspritze für müdlich und kreativ den Prozess der Erstellung dieser Broschüre, die deutsche Wissenschaft.
    [Show full text]